Abpro’s Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference
Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72 [Yahoo! Finance]
Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72
Abpro (NASDAQ:ABP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Abpro (NASDAQ:ABP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.